75N93025C00035
Definitive Contract
Overview
Government Description
ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY
Awardee
Awarding / Funding Agency
Place of Performance
Morrisville, NC 27560 United States
Pricing
Cost Plus Fixed Fee
Set Aside
None
Extent Competed
Full And Open Competition
Est. Average FTE
6
Related Opportunity
None
Locus Biosciences was awarded
Definitive Contract 75N93025C00035 (75N930-25-C-00035)
for Advance A Novel Therapeutic To A First-In-Human Clinical Study
worth up to $3,318,955
by the National Institute of Allergy and Infectious Diseases
in September 2025.
The contract
has a duration of 3 years 5 months and
was awarded
full & open
with
NAICS 541714 and
PSC AN12
via direct negotiation acquisition procedures with 16 bids received.
Status
(Open)
Last Modified 9/22/25
Period of Performance
9/24/25
Start Date
2/7/29
Current End Date
2/7/29
Potential End Date
Obligations
$3.3M
Total Obligated
$3.3M
Current Award
$3.3M
Potential Award
Award Hierarchy
Definitive Contract
75N93025C00035
Subcontracts
Activity Timeline
People
Suggested agency contacts for 75N93025C00035
Competition
Number of Bidders
16
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No
Other Categorizations
Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Large Business
Awardee UEI
CJKVLKZGX6F3
Awardee CAGE
7H2T2
Agency Detail
Awarding Office
75N930 NATIONAL INSTITUTES OF HEALTH NIAID
Funding Office
75N930
Created By
hhschargett
Last Modified By
hhsjbryan
Approved By
hhsjbryan
Legislative
Legislative Mandates
None Applicable
Performance District
NC-04
Senators
Thom Tillis
Ted Budd
Ted Budd
Representative
Valerie Foushee
Modified: 9/22/25